ETHAMIDE
LOE ApproachingNDAORALTABLET
Approved
Oct 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHAMIDE is an oral small-molecule tablet approved in 1966 by AbbVie with an unknown mechanism of action and indication profile. The drug's specific therapeutic target and patient population cannot be determined from available data.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), ETHAMIDE brand team is likely contracting and transitioning to lifecycle defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ETHAMIDE has zero linked job openings and offers limited growth career development due to its LOE-approaching status. Positions available are defensive in nature, focused on maximizing remaining market share and managing transition to generic competition.
Brand ManagerCommercial Operations Manager
Worked on ETHAMIDE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.